Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan, have a $15.15 exercise price, and expire on December 12, 2032. The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied and stated that the options vested on July 24, 2026, while time-based vesting continues on a monthly pro-rata basis over five years from the grant date.
Nektar Therapeutics’ Chief R&D Officer, Jonathan Zalevsky, sold 5,681 shares of Common Stock in an open-market transaction at $70.00 per share. After this sale, he directly holds 9,756 shares. The sale was executed on June 30, 2026 and was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Jonathan Zalevsky reported sales of 5,737 shares of Common Stock under a pre-arranged 10b5-1 plan.
The filing lists two transactions: 05/19/2026 sale of 199 shares for $13,036.49, and 06/15/2026 sale of 5,538 shares for $336,190.38. The record also shows 5,681 Restricted Stock Units dated 11/15/2020 with a reference date of 06/30/2026.
Nektar Therapeutics President & CEO Howard W. Robin reported open-market sales of 20,000 shares of common stock over two days in mid-June 2026. On June 16, 2026, he sold 5,303 shares at $59.97 and 4,697 shares at $60.71. On June 17, 2026, he sold 5,500 shares at $60.81 and 4,500 shares at $61.65. A footnote states that at least one transaction was made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating the sales were pre-arranged. After these transactions, Robin directly owns 55,045 Nektar shares, and an additional 28 shares are held indirectly by his spouse.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $60.71 per share on June 15, 2026, in multiple trades between $60.06 and $61.36.
After this sale, Zalevsky directly holds 15,437 shares of Nektar Therapeutics common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 13, 2026, indicating the sale was pre-arranged rather than timed discretionarily.
Nektar Therapeutics insider filing (Form 144) reports proposed sales. The notice lists two recent dispositions: 444 shares sold on 05/19/2026 for $29,084.53 and 10,000 shares sold on 06/16/2026 for $603,137.31. The filing also lists multiple Restricted Stock Vesting entries with specific vested share counts and dates.
NKTR: Notice of proposed insider sale and restricted‑stock vesting activity. The excerpt lists a proposed sale of 10,000 shares and related figures tied to the security, plus multiple past and scheduled restricted stock vesting events (examples: 2,991 vesting on 08/15/2025, 1,860 on 11/15/2021). The filing also records a sale by Howard Robin of 444 shares for $29,084.53.
Morgan Stanley Smith Barney LLC registered sale of 5,538 restricted stock units linked to common stock. The filing lists the RSU grant date 05/15/2021 and shows a prior disposition by Jonathan Zalevsky of 199 shares on 05/19/2026 for $13,036.49.
Nektar Therapeutics reported the results of its annual shareholder meeting held on June 4, 2026. Stockholders elected Howard W. Robin to the board to serve until the 2029 annual meeting, with 13,164,879 votes for, 4,975,288 against, and 286,175 abstentions, plus 4,588,835 broker non-votes.
Shareholders approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the shares of common stock authorized for issuance by 3,000,000 shares, with 13,160,661 votes for and 4,902,925 against. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 by 22,591,556 votes for and 118,592 against. A non-binding advisory resolution approving the Company’s executive compensation received 18,154,226 votes for and 161,005 against.
Nektar Therapeutics reported that Interim CFO Linda M. Rubinstein filed an initial statement of beneficial ownership as a company officer. This Form 3 filing lists her as an officer but does not report any purchases, sales, or other transactions in Nektar Therapeutics securities.